LifeMine raised $263 million across two venture rounds to advance a potentially safer, more convenient immunosuppressant for transplant rejection, as the biotech aims to address clinical limits of current regimens. The financing includes a previously unannounced $75 million Series D along with earlier rounds referenced by the company. The startup is led by scientist-entrepreneur Greg Verdine and plans to use the capital to move a new approach designed to reduce the burden of immunosuppression while maintaining graft protection. The funding further underscores investor interest in improving transplant outcomes through next-generation small-molecule or biologic immunomodulation. For transplant-focused biotechs, the size and structure of the round signals an ability to fund longer translational timelines—particularly where safety, tolerability, and workflow convenience are central differentiators.